WI Harper Group’s Senior Partner, Jimmy Lu, presents at the 3DHeals 2020 Global Summit

[vc_row][vc_column][vc_column_text]WI Harper Group | June 16, 2020[/vc_column_text][/vc_column][vc_column][vc_empty_space][/vc_column][/vc_row][vc_row][vc_column][vc_column_text css=”.vc_custom_1592333728285{background-color: #e4e4e4 !important;}”]On the weekend of June 5-6, 2020, 3DHeals held their annual Global Summit. Due to the pandemic, the summit was adapted to a virtual format, with keynote and startup presentations held over zoom. The 3DHeals Global Summit is the largest 100% virtual global healthcare 3D printing and bioprinting summit, bringing together over 70 speakers, hosting 4 workshops, and featuring startup pitch events.

Since its inception in 2015, the 3DHeals Global Summit focused its efforts on catering to a wide range of professionals, ranging from healthcare adopters, manufactures, executives and entrepreneurs. 3DHeals partnered with universities, healthcare industry leaders, and nonprofits worldwide to create a global fundraising and networking event focused on healthcare 3D printing, 3D bioprinting, bio-fabrication, and related emerging technologies.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text]Jimmy Lu, Senior Partner at WI Harper, was invited as one of five investors to speak in the “Something Ventured – Investor Perspectives” panel discussion and Q&A session. Due to Mr. Lu’s 20 years of experience in healthcare, high technology, and venture capital, he was asked to speak about his knowledge of the 3D Bioprinting Market and share some of his previous investment experiences in these fields.[/vc_column_text][vc_column_text]Specifically, Mr. Lu focused on Asia – as of 2018, Asia Pacific encompassed roughly 20-25% of the total Global 3D Bioprinting Market, and the region is slated for exponential growth. This anticipated growth is motivated by the presence of a target population, quick adoption of innovations, increased awareness about 3D printing technology, favorable government policies, and increasing investments.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_single_image source=”external_link” external_img_size=”800×400″ alignment=”center” custom_src=”https://wiharper.com/wp-content/uploads/2020/06/Picture1-1.png”][/vc_column][/vc_row][vc_row][vc_column][vc_column_text]Furthermore, Mr. Lu provided insights on current government initiatives related to 3D Printing in Asia. He specifically mentioned China’s “Made in China 2025”, the country’s initiative to move way from manufacturing low-quality goods to producing higher-value goods and services, which he anticipates will involve aspects of the 3D Bioprinting Industry. He also revealed South Korea’s plan to invest $37M USD into the 3D Bioprinting Industry, Japan’s estimation that the industry will reach 1 trillion JPY by 2030, and the Government of India’s collaboration with the US in the research and development of 3D Bioprinting in Regenerative Medicine. Another notable initiative in 3D Bioprinting included the National Additive Manufacturing Innovation Cluster in Singapore, which has engaged with over 1700 companies in this industry.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_single_image source=”external_link” external_img_size=”800×400″ alignment=”center” custom_src=”https://wiharper.com/wp-content/uploads/2020/06/Picture01.png”][/vc_column][/vc_row][vc_row][vc_column][vc_column_text]Mr. Lu continued to speak about some of the major 3D Bioprinting companies, including: Cyfuse Biomedical K.K from Japan, ROKIT Healthcare from South Korea, Regenovo Biotechnology Ltd from China, and Triaste from US/China. He then elaborated to describe the major innovations and investors for each of these companies.[/vc_column_text][vc_column_text]Mr. Lu conlcuded with an overview of the Healthcare 3D Printing industry and included some of his predictions regarding the industry’s projections. He noted that while US and European companies still dominate the Healthcare 3D Printing market, the field is expanding and being adopted rapidly in many leading Asian countries. He anticipates that Asian-based innovations in Healthcare 3D Printing will continue to accelerate and that, soon, more Asia Pacific Healthcare 3D Printing companies will be recognized as industry leaders and major players.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_single_image source=”external_link” external_img_size=”800×400″ alignment=”center” custom_src=”https://wiharper.com/wp-content/uploads/2020/06/IMG_6062.jpeg”][/vc_column][/vc_row][vc_row][vc_column][vc_empty_space height=”100px”][/vc_column][/vc_row][vc_row][vc_column][vc_column_text]

| About WI Harper Group: 

[/vc_column_text][vc_column_text]WI Harper is a pioneer and leading cross-border venture capital firm investing in early and expansion stage companies globally. With offices in San Francisco, Beijing, and Taipei, the firm actively oversees more than $1 billion in assets under management. Since inception nearly three decades ago, WI Harper has invested in over 400 startups and has successfully experienced more than 100 IPO and M&A exits.

We look for innovative companies and visionary founders in healthcare, technology and sustainability fields where there are high synergies and meaningful value added cross selling opportunities. While our healthcare team is presently honing on bioinformatics and digital biology, our technology team is focused blockchain, big data, analytics, artificial intelligence, AR/VR, IoT, robotics, drones, autonomous driving, as well as digital media and green energy projects.[/vc_column_text][/vc_column][/vc_row]

WI Harper Group’s Senior Partner, Jimmy Lu, presents at the 3DHeals 2020 Global Summit

Resvent Medical is a Shenzhen, China-based medical device and solution company focused on medical respiration & ventilation field, with its core management team having spun out of Mindray’s hospitals respiratory division, with over a decade of experience in homecare devices, clinical respiratory healthcare, intelligent information system, related consumable & accessories and value added services, and capable of building a globally competitive respiratory player – i.e. the RESMED of China.